• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Long Term Epilepsy Data Altering The Investment Case For LivaNova (LIVN)?

    Simply Wall St·10/31/2026 16:33:05
    Listen to the news
    • LivaNova reported that the journal Neuromodulation published full 36 month CORE VNS data in drug resistant epilepsy, covering 531 first time VNS Therapy implants across 61 sites in 16 countries with 80% retention at 36 months and no new safety concerns.
    • The study linked adjunctive VNS Therapy to a 76% median seizure reduction, a 64% responder rate, fewer seizure related hospitalizations and emergency visits, and self reported quality of life gains, which directly relates to therapy durability, real world resource use and potential appeal to clinicians and payers.
    • This article reviews how LivaNova's investment narrative could be influenced by multi year CORE VNS outcomes in drug resistant epilepsy care.

    Scan beyond LivaNova and this epilepsy update by sifting through 34 healthcare AI stocks that are reshaping how neurological and chronic conditions are treated with data driven therapies.

    LivaNova Investment Narrative Recap

    LivaNova appeals to shareholders who believe neuromodulation, cardiopulmonary hardware and digital tools can compound together over several years. The big swing factor is whether elevated 2026 capex of about US$135,000,000 turns into durable revenue and margin gains, rather than just heavier depreciation and softer free cash flow.

    The CORE VNS publication supports the epilepsy thesis around real world durability and healthcare resource use, which feeds directly into the near term catalyst of VNS procedure volumes and pricing. The bigger short term risk still sits with reimbursement and payer behavior, particularly given the high Medicare and Medicaid exposure.

    The 36 month CORE VNS outcomes are the announcement that matters most here. They tie directly into underpenetrated epilepsy VNS therapy, higher U.S. Medicare reimbursement and LivaNova’s plan for a broader digital ecosystem that starts in neuromodulation and extends into sleep apnea and depression over time.

    For catalysts, this data helps underpin the case that heavier neuromodulation and IT investment could support stickier hardware usage, more software and services and a steadier cardiopulmonary mix. The operational risk is that higher shipping costs, tariffs or a weaker procedure environment absorb these benefits before they reach earnings and cash conversion.

    LivaNova's narrative projects US$1.8b revenue and US$242.2 million earnings by 2029. This assumes 7.7% yearly revenue growth and an earnings increase of about US$53.6 million from US$188.6 million today.

    Uncover why LivaNova's fair value indicates a 15% potential upside to its current price, which could narrow quickly.

    NasdaqGS:LIVN 1-Year Stock Price Chart
    NasdaqGS:LIVN 1-Year Stock Price Chart

    Exploring Other Perspectives

    One angle that contrasts sharply with the CORE VNS optimism is free cash flow. The most cautious analysts were only pencilling in about 6.5% annual revenue growth and US$218.4 million of earnings by 2029 before this update, which effectively priced LivaNova around US$75. You can treat those lower figures as a stress test and explore which story you find more convincing.

    Explore another LivaNova fair value estimate, including one that suggests it could be worth just $90.55.

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond LivaNova?

    Once you have a handle on LivaNova, it can help to widen your watchlist and compare it with other opportunities that line up with your own risk profile and income goals.